Research programme: anti-infectives - NovaBay Pharmaceuticals

Drug Profile

Research programme: anti-infectives - NovaBay Pharmaceuticals

Alternative Names: Aganocide®; NVC-612; NVC-638; NVC-704; NVC-727

Latest Information Update: 05 Oct 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NovaBay Pharmaceuticals
  • Class Alkanesulfonic-acids; Chloramines; Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial infections; Mycoses; Onychomycosis

Most Recent Events

  • 19 Sep 2011 Antimicrobial data from ex vivo studies in corneal eye infections presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2011)
  • 01 Sep 2011 Antimicrobial data from in vitro studies in Bacterial infections & Mycoses presented at the 242nd American Chemical Society National Meeting (ACS-2011)
  • 16 Jun 2011 Aganocides™ are no longer licensed to Alcon worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top